The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while …
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while …
The Danish drugmaker filed for a preliminary injunction in New Jersey federal court, arguing Lilly’s Mounjaro ads compare …
The new autoinjector delivers an IV-equivalent 80 mg furosemide dose at home, and MannKind paired the approval with …
Starting July 31, large drugmakers face a 100 percent duty on patented medicines and active ingredients unless they …
A new market report projects 8.6 percent annual growth through 2031, driven by cell and gene therapy pipelines, …
Fresh capital will push DF-003 through Phase 3 for the rare inflammatory disorder ROSAH syndrome and DF-006 through …
The Trump administration’s pick for Assistant Secretary for Preparedness and Response has a history of linking hepatitis B …
New PMN310 data presented in London show measurable drops in cerebrospinal fluid amyloid-beta oligomers at three and 29 …
Four transactions above $10 billion and 38 acquisitions industrywide signal Big Pharma’s pivot from early bets to buying …
BL1107 failed to replicate visual function improvements seen in an earlier, smaller study, prompting the company to redirect …
